SCHEMBL1036703

SCHEMBL1036703

CC(C)(C)OC(=O)NC1CCOC1=O

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.54
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1271608 1.00 GAA (0.54) GAANFKB1NFKB2RELA
SCHEMBL4915249 1.00 GAA (0.54) GAANFKB1NFKB2RELA
SCHEMBL19824266 0.91 GAA (0.51) GAANFKB1NFKB2RELA
SCHEMBL518197 0.83 GAA (0.60) GAANFKB1NFKB2RELA
SCHEMBL555941 0.83 GAA (0.60) GAANFKB1NFKB2RELA
SCHEMBL9392474 0.83 GAA (0.60) GAANFKB1NFKB2RELA
SCHEMBL9151854 0.83
SCHEMBL14169230 0.82
SCHEMBL4973488 0.81 CTSS (0.45) GAA
SCHEMBL12318673 0.79 CD274 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240142876-A1 SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION JSR CORPORATION (JP) 2024-05-02 US disclosed
US-20240105451-A1 SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION JSR CORPORATION (JP) 2024-03-28 US disclosed
CN-107412740-B Polyethylene glycol based prodrugs of adrenomedullin and uses thereof 拜耳制药股份公司 2021-02-09 CN disclosed
EP-3109703-B1 PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, AND METHOD FOR FORMING PATTERN USING SAME TOKYO ELECTRON LTD (JP) 2020-12-30 EP disclosed
CN-111562720-A Photosensitizing chemically amplified resist material, method for forming pattern, semiconductor device, mask for lithography, and template for nanoimprint 东京毅力科创株式会社 2020-08-21 CN disclosed
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting TOKYO ELECTRON LIMITED (JP) 2018-07-17 US disclosed
EP-3109703-A1 PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, METHOD FOR FORMING PATTERN USING SAME, SEMICONDUCTOR DEVICE, MASK FOR LITHOGRAPHY, AND TEMPLATE FOR NANOIMPRINTING Tokyo Electron Limited (JP) 2016-12-28 EP disclosed
US-20160357103-A1 PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, METHOD FOR FORMING PATTERN USING SAME, SEMICONDUCTOR DEVICE, MASK FOR LITHOGRAPHY, AND TEMPLATE FOR NANOIMPRINTING TOKYO ELECTRON LIMITED (JP) 2016-12-08 US disclosed
CN-103998063-A Polyethylene glycol based prodrugs of adrenomedullin and uses thereof Bayer Pharma AG 2014-08-20 CN disclosed
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
EP-2276731-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 Boehringer Ingelheim International GmbH (DE) 2011-01-26 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed
WO-2009126675-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 WO disclosed
EP-0691953-B1 1-AMIDINOPHENYL-PYRROLIDONES/ PIPERIDINONES AS PLATELET AGGREGATION INHIBITORS SEARLE & CO (US) 2000-08-02 EP disclosed
US-5721366-A PHENYLAMIDINE DERIVATIVES G. D. SEARLE & CO (US) 1998-02-24 US disclosed
WO-1994022820-A1 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS G.D. SEARLE & CO. (US) 1994-10-13 WO disclosed
US-3968233-A α-Amino-γ-butyrolactones as sedatives ISTITUTO CHEMIOTERAPICO ITALIANO (IT) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10025187-B2 Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting ASIC1, ASIC3, CLTA GAA 863/4885NFKB1 3763/4885NFKB2 4084/4885
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 GAA 272/4885NFKB1 4513/4885NFKB2 4268/4885
US-20140155376-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK2 GAA 3303/4885NFKB1 269/4885NFKB2 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.